Shots: Novo Nordisk to acquire in all-cash transaction, making a total deal value ~$2.1B which included $725M as upfront and a remaining as regulatory and sales milestones The acquisition of Corvidia Therapeutics along with its lead candidate, ziltivekimab allow the Novo Nordisk to expand its footprints across cardiometabolic diseases Ziltivekimab is a fully human mAb […]Read More
